Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”
Titel:
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”
Auteur:
Stadler, Rudolf Roccuzzo, Gabriele Ortiz-Romero, Pablo Bagot, Martine Quaglino, Pietro Guenova, Emmanuella Jonak, Constanze Papadavid, Evangelia Stranzenbach, René Marreaud, Sandrine Musoro, Jammbe Casas-Martin, Jose Murray, Duncan Drennan, Samantha Hear, Jimmy Van Moss, Paul Sartori, Delphine Battistella, Maxime Willemze, Rein Scarisbrick, Julia Knobler, Robert